PMID- 28143792 OWN - NLM STAT- MEDLINE DCOM- 20171207 LR - 20220410 IS - 1879-0542 (Electronic) IS - 0165-2478 (Linking) VI - 183 DP - 2017 Mar TI - 2003-2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer. PG - 37-43 LID - S0165-2478(16)30326-1 [pii] LID - 10.1016/j.imlet.2017.01.014 [doi] AB - Dendritic cells (DCs) and cytokine-induced killer (CIK) cells have both shown activity as immunotherapy in some malignancies. Our aim was to prospective assess the effect of this immunotherapy in patients with stage IV breast cancer. Between Aug 2003 and Dec 2013, we collected 368 patients who met inclusion criteria and divided into immunotherapy group (treatment group: 188 patients) and chemotherapy group (control group: 180 patients). DCs were prepared from the mononuclear cells isolated from patients in the treatment group using IL-2/GM-CSF and were loaded with tumour antigens; CIK cells were prepared by incubating peripheral blood lymphocytes with IL-2, IFN-gamma, and CD3 antibodies. After the patients had received low-dose chemotherapy, those in the treatment group also received the DC-CIK therapy, which was repeated four times in a fortnight to form one cycle. At least three cycles of DC-CIK therapy were given. Immune function was measured in treatment group patients' sera. Disease-free survival (DFS) and Overall survival (OS) after the diagnosis of stage IV breast cancer was assessed after a 10-year follow-up. The result demonstrated that immune function is obviously enhanced after DC-CIK therapy. By Cox regression analysis, DC-CIK therapy reduced the risk of disease progression (p<0.01) with an increased OS (p<0.01). After low-dose chemotherapy, active immunization with DC-CIK immunotherapy is a potentially effective approach for the control of tumour growth in stage IV breast cancer patients. CI - Copyright (c) 2017 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved. FAU - Lin, Mao AU - Lin M AD - Department of Biotherapy Center, Fuda Cancer Hospital, Jinan University School of Medicine, NO. 2 TangDe Xi Rd., Tianhe District, Guangzhou, China; Department of Fuda Cancer Institute, Guangzhou, NO. 2 TangDe Xi Rd., Tianhe District, Guangzhou, China. FAU - Liang, Shuzhen AU - Liang S AD - Department of Biotherapy Center, Fuda Cancer Hospital, Jinan University School of Medicine, NO. 2 TangDe Xi Rd., Tianhe District, Guangzhou, China; Department of Fuda Cancer Institute, Guangzhou, NO. 2 TangDe Xi Rd., Tianhe District, Guangzhou, China. FAU - Jiang, Feng AU - Jiang F AD - Department of Fuda Cancer Institute, Guangzhou, NO. 2 TangDe Xi Rd., Tianhe District, Guangzhou, China. FAU - Xu, Jiongyuan AU - Xu J AD - Department of Biotherapy Center, Fuda Cancer Hospital, Jinan University School of Medicine, NO. 2 TangDe Xi Rd., Tianhe District, Guangzhou, China. FAU - Zhu, Weibing AU - Zhu W AD - Department of Biotherapy Center, Fuda Cancer Hospital, Jinan University School of Medicine, NO. 2 TangDe Xi Rd., Tianhe District, Guangzhou, China. FAU - Qian, Wei AU - Qian W AD - Department of Biotherapy Center, Fuda Cancer Hospital, Jinan University School of Medicine, NO. 2 TangDe Xi Rd., Tianhe District, Guangzhou, China. FAU - Hu, Yong AU - Hu Y AD - Department of Biotherapy Center, Fuda Cancer Hospital, Jinan University School of Medicine, NO. 2 TangDe Xi Rd., Tianhe District, Guangzhou, China. FAU - Zhou, Zhanchun AU - Zhou Z AD - Department of Biotherapy Center, Fuda Cancer Hospital, Jinan University School of Medicine, NO. 2 TangDe Xi Rd., Tianhe District, Guangzhou, China. FAU - Chen, Jibing AU - Chen J AD - Department of Biotherapy Center, Fuda Cancer Hospital, Jinan University School of Medicine, NO. 2 TangDe Xi Rd., Tianhe District, Guangzhou, China; Department of Fuda Cancer Institute, Guangzhou, NO. 2 TangDe Xi Rd., Tianhe District, Guangzhou, China. Electronic address: linmaogz@163.com. FAU - Niu, Lizhi AU - Niu L AD - Department of Fuda Cancer Institute, Guangzhou, NO. 2 TangDe Xi Rd., Tianhe District, Guangzhou, China. Electronic address: little.silly.ding@qq.com. FAU - Xu, Kecheng AU - Xu K AD - Department of Fuda Cancer Institute, Guangzhou, NO. 2 TangDe Xi Rd., Tianhe District, Guangzhou, China. FAU - Lv, Youyong AU - Lv Y AD - Peking University, Central Lab of Cancer Hospital, Beijing, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20170129 PL - Netherlands TA - Immunol Lett JT - Immunology letters JID - 7910006 RN - 0 (Antigens, Neoplasm) RN - 0 (Cancer Vaccines) RN - 0 (Cytokines) SB - IM MH - Adult MH - Aged MH - Antigens, Neoplasm/*immunology MH - Breast Neoplasms/diagnosis/*immunology/mortality/*therapy MH - Cancer Vaccines/*immunology/therapeutic use MH - Combined Modality Therapy MH - Cytokine-Induced Killer Cells/*immunology/metabolism MH - Cytokines/metabolism MH - Dendritic Cells/*immunology/metabolism MH - Female MH - Humans MH - *Immunotherapy/adverse effects/methods MH - Kaplan-Meier Estimate MH - Lymphocyte Count MH - Middle Aged MH - Neoplasm Metastasis MH - Neoplasm Staging MH - Proportional Hazards Models MH - Retrospective Studies MH - Treatment Outcome OTO - NOTNLM OT - Cytokine-induced killer OT - DFS OT - Dendritic cell OT - Immunotherapy OT - OS OT - Stage IV breast cancer EDAT- 2017/02/02 06:00 MHDA- 2017/12/08 06:00 CRDT- 2017/02/02 06:00 PHST- 2016/12/07 00:00 [received] PHST- 2017/01/24 00:00 [revised] PHST- 2017/01/24 00:00 [accepted] PHST- 2017/02/02 06:00 [pubmed] PHST- 2017/12/08 06:00 [medline] PHST- 2017/02/02 06:00 [entrez] AID - S0165-2478(16)30326-1 [pii] AID - 10.1016/j.imlet.2017.01.014 [doi] PST - ppublish SO - Immunol Lett. 2017 Mar;183:37-43. doi: 10.1016/j.imlet.2017.01.014. Epub 2017 Jan 29.